Literature DB >> 35846417

99mTc-PSMA Left Behind: a Call for Collaboration.

Soroush Zarehparvar Moghadam1, Emran Askari2, Kamran Aryana2.   

Abstract

Entities:  

Year:  2022        PMID： 35846417      PMCID： PMC9276883          DOI： 10.1007/s13139-022-00753-7

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


× No keyword cloud information.
  8 in total

1.  177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy.

Authors:  Kamran Aryana; Soroush Zarehparvar Moghadam; Roham Salek; Ghasemali Divband
Journal:  Clin Nucl Med       Date:  2018-04       Impact factor: 7.794

2.  99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer.

Authors:  Babak Fallahi; Niloufar Khademi; Najme Karamzade-Ziarati; Armaghan Fard-Esfahani; Alireza Emami-Ardekani; Saeed Farzanefar; Mohammad Eftekhari; Davood Beiki
Journal:  Clin Nucl Med       Date:  2021-02-01       Impact factor: 7.794

3.  Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study.

Authors:  Soroush Zarehparvar Moghadam; Emran Askari; Ghasemali Divband; Sara Shakeri; Kamran Aryana
Journal:  Rev Esp Med Nucl Imagen Mol (Engl Ed)       Date:  2021-09-12

4.  Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.

Authors:  Hendrik Rathke; Ali Afshar-Oromieh; Frederik Lars Giesel; Christophe Kremer; Paul Flechsig; Sabine Haufe; Walter Mier; Tim Holland-Letz; Maximilian De Bucourt; Thomas Armor; John W Babich; Uwe Haberkorn; Clemens Kratochwil
Journal:  J Nucl Med       Date:  2018-01-25       Impact factor: 10.057

5.  Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.

Authors:  Andrei Gafita; Wolfgang P Fendler; Wang Hui; Shahneen Sandhu; Manuel Weber; Rouzbeh Esfandiari; Jeremie Calais; Isabel Rauscher; Hendrik Rathke; Robert Tauber; Ebrahim S Delpassand; Wolfgang A Weber; Ken Herrmann; Johannes Czernin; Matthias Eiber; Michael S Hofman
Journal:  Eur Urol       Date:  2020-06-10       Impact factor: 20.096

6.  Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study.

Authors:  Szabolcs Urbán; Catherine Meyer; Magnus Dahlbom; István Farkas; Gábor Sipka; Zsuzsanna Besenyi; Johannes Czernin; Jeremie Calais; László Pávics
Journal:  J Nucl Med       Date:  2020-12-04       Impact factor: 10.057

7.  Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.

Authors:  Batool Albalooshi; Mouza Al Sharhan; Fariborz Bagheri; Shabna Miyanath; Bhavna Ray; Muhammed Muhasin; Seyed Rasoul Zakavi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

8.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.